Title:
POLYPEPTIDE COMPOUND SPECIFICALLY TARGETING SORT1, AND DRUG CONJUGATE THEREOF
Document Type and Number:
WIPO Patent Application WO/2023/165476
Kind Code:
A1
Abstract:
A targeting peptide specifically targeting Sortilin/SORT1 protein, and a targeting peptide-drug conjugate comprising the targeting peptide. The targeting peptide is a linear peptide or cyclic peptide with non-natural chemical modification, and can improve the half-life period of the targeting peptide-drug conjugate and improve the stability thereof. The targeting peptide-drug conjugate can specifically bind to the target protein Sortilin/SORT1 with high affinity, so as to effectively kill a tumor expressing Sortilin/SORT1, and a novel anti-tumor targeting drug is provided for the field of tumor treatment.
Inventors:
DONG ZHICHAO (CN)
CHEN CHANGFA (CN)
CHEN CHANGFA (CN)
Application Number:
PCT/CN2023/078789
Publication Date:
September 07, 2023
Filing Date:
February 28, 2023
Export Citation:
Assignee:
SHANGHAI SMARTIDE BIOTECHNOLOGY CO LTD (CN)
International Classes:
A61K31/337; C07K7/08; A61K47/64; A61P35/00; C07K1/04
Domestic Patent References:
| WO2021108929A1 | 2021-06-10 |
Foreign References:
| CN113286820A | 2021-08-20 | |||
| CN108473541A | 2018-08-31 | |||
| CN106334194A | 2017-01-18 | |||
| EP2954934A1 | 2015-12-16 |
Other References:
DEMEULE MICHEL, CHARFI CYNDIA, CURRIE JEAN‐CHRISTOPHE, LAROCQUE ALAIN, ZGHEIB ALAIN, KOZELKO SOPHIE, BÉLIVEAU RICHARD, MARSOLAIS C: "TH1902, a new docetaxel‐peptide conjugate for the treatment of sortilin‐positive triple‐negative breast cancer", CANCER SCIENCE, JAPANESE CANCER ASSOCIATION, TOKYO, JP, vol. 112, no. 10, 1 October 2021 (2021-10-01), JP , pages 4317 - 4334, XP093087938, ISSN: 1347-9032, DOI: 10.1111/cas.15086
Attorney, Agent or Firm:
XU & PARTNERS , LLC. et al. (CN)
Download PDF: